It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
This work has been published in the journal ‘ACS applied materials and interface’
All India Institute of Ayurveda hosts ministers and showcase their achievements
Board approves fundraise of Rs 1500 crore
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
